200% tariff after 2 years relief! Trump’s new drug plan has increased the concern of India’s pharma industry. Could the ‘world’s pharmacy’ lose its biggest market?
Trump Drug 200 Percent Tariff: A huge earthquake has occurred in the global business and health sector. US President Donald Trump has made such an aggressive economic announcement, which has given sleepless nights to the Indian pharmaceutical industry. Trump has introduced a very controversial and shocking tariff plan on generic drugs. Under this, 0% duty has been kept on imported generic medicines for two years, but after that this duty will directly increase to 100% and ultimately to a whopping 200%. Let us understand what this step of Trump means for India, which is called the ‘Pharmacy of the World’ and how it can shake the global health system.
Two-year ‘flickering’ timer: What dreadful warning is hidden under the guise of relief?
According to this new policy of Trump, there will be no tax on generic medicines imported into America for the next two years. At first glance this may seem like a relief, but in reality it is like a time-bomb. Trump has made it clear that this two-year period is not an exemption, but a final warning to foreign pharmaceutical companies to wrap up their entire production base and shift it to America. If companies do not move their manufacturing to America within two years, they will face a heavy import duty of 100% from 2028, which will later be increased to 200%. Since the Covid-19 pandemic, there has been increasing concern in America that it is overly dependent on foreign countries for medicines. Now Trump wants to end this dependence by force.
Scroll to load tweet…
Why is India at the center of biggest concern?
India is one of the world’s largest generic drug producers. A large number of generic drugs sold in the US market come from Indian companies. India plays an important role in the supply of many essential medicines like antibiotics, diabetes, heart disease and cancer. If 100% or 200% tariffs are imposed in the future, the price of Indian drugs could increase significantly in the US. There will be a danger of this affecting the competitive ability of Indian companies.
Read this also… What about bank loan, property or suicide note? Mysore businessman
Crisis looms over pharma giants: The reputation of these big giants of India is at stake.
This news is no less than a big shock for India, because America is the largest export market of the Indian pharmaceutical industry. Most of the generic drugs sold in the US—such as antibiotics, diabetes drugs, and serious cancer drugs—come from India. With this decision of Trump, the revenue model of many top pharma companies of India is under direct threat. According to analysts, the giant companies on which this could have the deepest and most serious impact include:
- Sun Pharma
- Dr. Reddy’s Laboratories
- Aurobindo Pharma
- Lupine
- Zydus Lifesciences
- Cipla, Glenmark and Torrent Pharma.
Experts say that the companies which already have some manufacturing plants in America will somehow withstand this crisis. But, the small and medium companies which are completely dependent on manufacturing medicines in India and sending them to America, their very existence may be in danger.
Will American patients face punishment? Medicine prices may skyrocket
There is another dark side to this entire strategy, which is scaring the American citizens themselves. Most of the drugs prescribed by doctors in the US are generic because they are much cheaper than branded drugs. If a massive 200% tariff is implemented after two years, the cost of cheap medicines coming from India will increase three times. Drug companies will not bear this additional financial burden themselves, but will instead pass it on to American distributors, insurance companies, and ultimately poor patients. Additionally, it is impossible to shift pharmaceutical manufacturing overnight like electronics, requiring stringent US FDA approvals and multimillion-dollar infrastructure. Experts have warned that if companies stop supplies to America due to fear of losses, there could be a severe shortage of life-saving medicines.
Can Indian companies increase production in America?
Some Indian companies are already producing in the US, but shifting manufacturing on a large scale will not be easy. This will require billions of rupees of investment, new factories, trained employees, US regulatory approvals and a strong supply chain. This change may prove particularly challenging for small and medium companies.
The last move on the diplomatic chessboard: will talks lead to a solution?
Now the question arises whether India will be able to get out of this maze? Donald Trump has an old habit of often announcing big tariffs to create pressure in trade negotiations. It is possible that this may be a ploy to get other deals from countries like India and China. This issue is now going to be on top in future India-US bilateral trade talks. The Indian government, on behalf of New Delhi, will definitely put forward a demand to the US administration for special exemption, lower tariff rates for life-saving medicines or further extension of this two-year transition period. However, there may not be any immediate crisis, but in the long run, it has emerged as the biggest challenge of the century for the Indian pharma sector.
Is this just a pressure tactic or a major change?
Trump has previously used tariffs as a pressure weapon in trade negotiations. But this time the policy of promoting domestic drug manufacturing in America is getting the support of both the major political parties. Therefore, it would be premature to consider this as just a negotiation strategy.
Read this also….Sikkim Tunnel Accident: 20 workers died due to methane gas explosion, 5 still trapped, what happened in the tunnel?